These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66 related articles for article (PubMed ID: 9314087)
1. Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. Brewster ME; Pop E; Foltz RL; Reuschel S; Griffith W; Amselem S; Biegon A Int J Clin Pharmacol Ther; 1997 Sep; 35(9):361-5. PubMed ID: 9314087 [TBL] [Abstract][Full Text] [Related]
2. Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220. Gershkovich P; Qadri B; Yacovan A; Amselem S; Hoffman A Eur J Pharm Sci; 2007 Aug; 31(5):298-305. PubMed ID: 17560096 [TBL] [Abstract][Full Text] [Related]
4. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. Achiron A; Miron S; Lavie V; Margalit R; Biegon A J Neuroimmunol; 2000 Jan; 102(1):26-31. PubMed ID: 10626663 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and brain uptake of AM-36, a novel neuroprotective agent, following intravenous administration to rats. Nicolazzo JA; Nguyen TT; Katneni K; Steuten JA; Smith G; Jarrott B; Callaway JK; Charman SA J Pharm Pharmacol; 2008 Feb; 60(2):171-8. PubMed ID: 18237464 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Marzo A; Dal Bo L; Monti NC; Crivelli F; Ismaili S; Caccia C; Cattaneo C; Fariello RG Pharmacol Res; 2004 Jul; 50(1):77-85. PubMed ID: 15082032 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and bioavailability of cefquinome in healthy piglets. Li XB; Wu WX; Su D; Wang ZJ; Jiang HY; Shen JZ J Vet Pharmacol Ther; 2008 Dec; 31(6):523-7. PubMed ID: 19000274 [TBL] [Abstract][Full Text] [Related]
8. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645 [TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Aneja R; Dhiman N; Idnani J; Awasthi A; Arora SK; Chandra R; Joshi HC Cancer Chemother Pharmacol; 2007 Nov; 60(6):831-9. PubMed ID: 17285314 [TBL] [Abstract][Full Text] [Related]
10. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971 [TBL] [Abstract][Full Text] [Related]
11. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2. Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614 [TBL] [Abstract][Full Text] [Related]
12. Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia. Leker RR; Shohami E; Abramsky O; Ovadia H J Neurol Sci; 1999 Jan; 162(2):114-9. PubMed ID: 10202976 [TBL] [Abstract][Full Text] [Related]
13. Water-soluble combinations of dexanabinol: prodrugs and analogs. Pop E Pharmazie; 2000 Mar; 55(3):167-71. PubMed ID: 10756534 [TBL] [Abstract][Full Text] [Related]
14. Proliposomal Ropivacaine Oil: Pharmacokinetic and Pharmacodynamic Data After Subcutaneous Administration in Volunteers. Ginosar Y; Haroutounian S; Kagan L; Naveh M; Aharon A; Davidson EM Anesth Analg; 2016 May; 122(5):1673-80. PubMed ID: 27057798 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice. Lukka PB; Paxton JW; Kestell P; Baguley BC Cancer Chemother Pharmacol; 2010 May; 65(6):1145-52. PubMed ID: 19774378 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease. Smith WB; Dowell JA; Pratt RD Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion. Wade M; Baker FJ; Roscigno R; DellaMaestra W; Arneson CP; Hunt TL; Lai AA J Clin Pharmacol; 2004 May; 44(5):503-9. PubMed ID: 15102871 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of arundic acid, an astrocyte modulating agent, in acute ischemic stroke. Ishibashi H; Pettigrew LC; Funakoshi Y; Hiramatsu M J Clin Pharmacol; 2007 Apr; 47(4):445-52. PubMed ID: 17389553 [TBL] [Abstract][Full Text] [Related]
19. Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine. Khalili P; Naimi E; Sun WY; Knaus EE; Wiebe LI Biopharm Drug Dispos; 2003 Dec; 24(9):385-95. PubMed ID: 14689467 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]